Results 181 to 190 of about 18,251 (231)
Some of the next articles are maybe not open access.
Preclinical pharmacology of alendronate
Osteoporosis International, 1993This brief review summarizes some of the preclinical findings of studies aimed at assessing the efficacy and safety of the aminobisphosphonate alendronate (ALN) in preventing or restoring the bone loss caused by calcium or estrogen deficiency. Mode of action studies show that ALN localizes at sites of bone resorption and inhibits osteoclastic activity.
G A, Rodan, J G, Seedor, R, Balena
openaire +2 more sources
Intermittent Dosing of Alendronate
Annals of Pharmacotherapy, 2001OBJECTIVE: To review data describing use of intermittent dosing of alendronate. DATA SOURCES: A comprehensive literature search was conducted using MEDLINE (1966–May 2001) and EMBASE (1974–May 2001) databases to identify all ...
E C, Tsun, A M, Heck
openaire +2 more sources
Drugs of Today, 2003
Alendronate, a bisphosphonate that potently inhibits bone resorption, has been shown in long-term clinical trials to be an effective treatment for osteoporosis, increasing bone mineral density and substantially reducing the incidence of both vertebral and nonvertebral fractures, including hip fractures, mostly using a daily dosage regimen.
openaire +2 more sources
Alendronate, a bisphosphonate that potently inhibits bone resorption, has been shown in long-term clinical trials to be an effective treatment for osteoporosis, increasing bone mineral density and substantially reducing the incidence of both vertebral and nonvertebral fractures, including hip fractures, mostly using a daily dosage regimen.
openaire +2 more sources
Postmenopausal osteoporosis and alendronate
Maturitas, 2004Osteoporosis is a systemic metabolic disorder associated with a decreased bone mass and resistance. Bisphosphonates suppress bone resorption and bone turnover by a mechanism that depends on their structure. They are characterized by low gastrointestinal absorption. In postmenopausal women, alendronate (ALN) reduces bone resorption markers and increases
openaire +2 more sources
Clinical calcium, 2008
Alendronate is one of a few pharmaceutical agents that have evidence to protect both vertebral and non-vertebral fracture. Here I review its effects on fracture prevention, as well as on surrogate markers such as bone mineral density, height loss, metabolic bone markers. Its effects on activities of daily living and quality of life will also be touched
openaire +1 more source
Alendronate is one of a few pharmaceutical agents that have evidence to protect both vertebral and non-vertebral fracture. Here I review its effects on fracture prevention, as well as on surrogate markers such as bone mineral density, height loss, metabolic bone markers. Its effects on activities of daily living and quality of life will also be touched
openaire +1 more source
Alendronate — A new bisphosphonate
Osteoporosis International, 1996These results confirm that alendronate is a potent inhibitor of bone resorption which exerts beneficial effects in postmenopausal women with osteoporosis. It must be borne in mind that the current results relate to clinical trials in ‘ideal’ patients and experience still needs to be gained in treating patients with multiple coexisting problems, who are
openaire +2 more sources